Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Nucleome Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","amount":"$43.2 million","upfrontCash":"Undisclosed","newsHeadline":"Nucleome Therapeutics Raises Oversubscribed \u00a337.5 Million Series A Financing to Decode the Dark Matter of The Human Genome and Deliver First-In-Class Precision Medicines","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by Nucleome Therapeutics

    Menu

    Nucleome Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Nucleome Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nucleome Therapeutics Raises Oversubscribed £37.5 Million Series A Financing to Decode the Dark Matter of The Human Genome and Deliver First-In-Class Precision Medicines

              Details:

              The funds will be used to advance the Company’s autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.

              Lead Product(s): Undisclosed

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: M Ventures

              Deal Size: $43.2 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing October 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY